SecBot SecBot
SECBOTREPLAY Home › Report › CTMX

CTMX · CytomX Therapeutics announced a public offering of $250.0 million in…

CytomX Therapeutics Inc. · PRESS-RELEASE filed Mar 16, 2026 at 16:04 ET

At the news

BEARISHIMPACT 7/10

PRESS-RELEASE filed Mar 16, 2026 at 16:04 ET

CytomX Therapeutics announced a public offering of $250.0 million in common stock and pre-funded warrants, with an additional $37.5 million option for underwriters to purchase more shares. The offering is expected to dilute existing shareholders and is subject to market conditions.

  • CytomX announced a public offering of $250.0 million in common stock and pre-funded warrants.
  • Underwriters have a 30-day option to purchase up to an additional $37.5 million in shares.
  • All securities are being offered directly by CytomX, indicating primary issuance and not a secondary sale.
  • Proceeds will likely be used for general corporate purposes, R&D, or clinical trial funding, though specific use was not detailed in the release.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access